2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

702. CAR-T Cell Therapies: Basic and Translational: Poster I

Program: Poster Abstract Session
Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Imaging, Molecular Testing, Omics Technologies, Bioinformatics, Cell Expansion, Computational Biology, Emerging Technologies, Gene Editing, Profiling, Treatment Considerations, Combination Therapy, Drug Development, Biological Therapies, Natural Killer (NK) Cell Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Gene Therapy, Immunotherapy, Non-Biological Therapies, Pharmacology, Adverse Events, Artificial Intelligence (AI), Deep Learning, Generative AI, Machine Learning, Biological Processes, Pathogenesis, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Quality Improvement, Diseases, Immunology, Autoimmune Disorders, GVHD, Infectious Diseases, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, ALL, Non-Hodgkin Lymphoma, B Cell Lymphoma, Aggressive Lymphoma, Research, Fundamental Science, AML, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Real-World Evidence, Study Population, Human, Adult, Pediatric, Animal Model
PAPER

2376 Circadian disruption exacerbates CAR-T-associated neurotoxicity through JAK1/STAT3-mediated loss of BMAL1-dependent brain endothelial homeostasis

Wanying Zhang, PhD, Zi Wang2, Zhaozhao Chen3, Yinqiang Zhang4, Heng Mei, MD, PhD5
1 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background

The incidence and severity of immune effector cell-associated neurotoxicity syndrome (ICANS) vary substantially among patients receiving comparable CAR-T therapy, suggesting that treatment-related inflammation alone cannot fully explain this heterogeneity. The host factors determining ICANS susceptibility remain poorly understood. Given the emerging role of circadian disruption in neuroinflammation and neurological disorders, we investigated whether circadian dysregulation represents a vulnerability state for CAR-T-associated neurotoxicity and defined its underlying mechanisms.

Methods

We integrated human single-cell transcriptomic analyses with complementary in vivo and in vitro models. Cerebrospinal fluid single-cell RNA-sequencing data were analyzed using circadian rhythm disruption (CRD) scores to quantify circadian dysregulation and evaluate its association with ICANS development and severity (no ICANS, n=4; ICANS, n=5). Syngeneic non-Hodgkin lymphoma ICANS models were established under circadian-intact or circadian-disrupted conditions to assess neurobehavioral outcomes, blood-brain barrier integrity, and neural injury. Brain single-cell profiling was further performed to identify CRD-responsive cellular populations and molecular programs.

Mechanistic studies were conducted in serum-shock-synchronized human brain microvascular endothelial cells subjected to circadian perturbation, followed by stimulation with supernatants derived from CAR-T/Raji co-cultures. Endothelial barrier function, inflammatory responses, tight-junction integrity, and clock regulation were evaluated, followed by transcriptomic analysis and pathway validation. The role of JAK1 signaling was examined using the selective inhibitor golidocitinib, combined with BMAL1 loss- and gain-of-function approaches to define its contribution to endothelial dysfunction and therapeutic response. The protective effects of JAK1 inhibition were subsequently validated in vivo using the circadian-disrupted ICANS model.

Results

Human cerebrospinal fluid single-cell analysis revealed that CRD scores increased with ICANS development and severity, linking circadian dysregulation to neurotoxicity susceptibility. In a syngeneic CAR-T model, experimental circadian disruption exacerbated neurobehavioral deficits, including impaired spatial learning, recognition memory, and anxiety-like behavior. These abnormalities were accompanied by increased blood-brain barrier disruption, synaptic ultrastructural damage, and neuronal injury, demonstrating that circadian disruption heightens neurovascular and neural vulnerability during CAR-T therapy.

To define the cellular basis underlying circadian disruption-associated neurotoxicity, brain single-cell profiling was performed. CRD-associated transcriptional alterations were predominantly localized to blood-brain barrier-associated populations, with endothelial cells exhibiting impaired barrier-maintenance programs and enhanced inflammatory activation. Circadian perturbation of human brain microvascular endothelial cells recapitulated this phenotype in vitro, resulting in impaired barrier function, reduced tight-junction protein expression, increased inflammatory activation, and suppression of BMAL1. Transcriptomic and protein analyses further identified enhanced JAK1-STAT3 signaling as a defining molecular feature of the CRD-induced endothelial state. Mechanistically, selective JAK1 inhibition with golidocitinib restored BMAL1 expression, preserved tight-junction proteins, and rescued endothelial barrier dysfunction. BMAL1 depletion abolished these protective effects, whereas BMAL1 overexpression partially restored barrier integrity, functionally positioning BMAL1 downstream of JAK1-STAT3 signaling. Finally, pharmacological inhibition of JAK1 with golidocitinib ameliorated CRD-associated neurological deficits, preserved blood-brain barrier integrity, and reduced synaptic and neuronal injury in vivo, highlighting the JAK1-STAT3-BMAL1 axis as a potential therapeutic target for circadian disruption-mediated ICANS susceptibility.

Conclusion

Our findings identify circadian disruption as a host determinant of ICANS susceptibility and severity by driving JAK1-STAT3-dependent loss of BMAL1-mediated endothelial barrier homeostasis. This clinically actionable mechanism supports CRD-guided risk stratification and selective JAK1 inhibition with golidocitinib as a targeted strategy for the prevention and mitigation of ICANS.

Wanying Zhang, PhD: No relevant conflicts of interest to declare.